drugset / Trial / NCT00727103
Varenicline Treatment in Alcohol and Nicotine Dependent Patients With Schizophrenia
Phase 4
Completed
10 enrolled
State University of New York - Upstate Medical University
National Alliance for Research on Schizophrenia and Depression · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The aim of the proposed pilot study is to find out whether varenicline (ChantixTM) treatment decreases alcohol use and smoking in patients with schizophrenia or schizoaffective disorder. Varenicline may also improve cognition (memory and concentration) and negative symptoms (e.g. poor attention, poverty of speech, apathy, affective flattening, anhedonia) in patients with schizophrenia and comorbid nicotine and alcohol dependence.
Timeline
- Start
- 2008-07
- Primary completion
- 2011-05
- Completion
- 2011-05
Publications
- Results Meszaros ZS, Abdul-Malak Y, Dimmock JA, Wang D, Ajagbe TO, Batki SL. Varenicline treatment of concurrent alcohol and nicotine dependence in schizophrenia: a randomized, placebo-controlled pilot trial. J Clin Psychopharmacol. 2013 Apr;33(2):243-7. doi: 10.1097/JCP.0b013e3182870551.
- Livingstone-Banks J, Fanshawe TR, Thomas KH, Theodoulou A, Hajizadeh A, Hartman L, Lindson N. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2023 May 5;5(5):CD006103. doi: 10.1002/14651858.CD006103.pub8.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Varenicline | Small molecule | 1 mg | Oral |